The RENOVATE trial set out to answer a high-impact question across five distinct etiologic groups: Is HFNC non-inferior to BPAP (NIV) for preventing intubation or death in acute respiratory failure?

The post REBEL CAST – RENOVATE Trial: HFNC vs BPAP in Acute Respiratory Failure appeared first on REBEL EM - Emergency Medicine Blog.